Skip to content
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
Homepage
Open navigation
  • Technology
    • The platform
    • Artificial Intelligence
    • BioClick
    • Nobel Prize heritage
    • Biosolution phases
    • Scientific papers
    • Patents
  • Pipeline
    • Pipeline overview
    • NCT: Over-the-Counter
    • NCT: Pharma
    • Cannabinoids
    • Santalene
    • Become a partner
  • Investors
    • Stock information
    • News
    • Email signup
    • Investor Relation Contacts
    • Governance
    • SEC Filings
    • Video
  • About
    • Leadership team
    • History
    • Jobs
    • Policies
    • Contact
  • News
    • Latest news
    • Media coverage
    • Investor news
    • News archive
ARCHIVE: CEO buys IZTC stock
investorARCHIVE
ARCHIVE: CEO buys IZTC stockJan 21, 2025 12:00:00 AM
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Go To Market Strategy - part 3 of a fireside chat about InvizyneJan 15, 2025 12:00:00 AM
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Using AI for Enzyme Engineering - Part 2 of a Fireside Chat About InvizyneJan 7, 2025 12:00:00 AM
ARCHIVE: Looking back at 2024 - part 1 of a fireside chat about Invizyne
heltzeninvestorvideoARCHIVE
ARCHIVE: Looking back at 2024 - part 1 of a fireside chat about InvizyneDec 31, 2024 12:00:00 AM
ARCHIVE: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
biofuelpress releaseARCHIVE
ARCHIVE: Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel CapabilitiesNov 19, 2024 12:00:00 AM
ARCHIVE: Invizyne Technologies Announces Closing of Initial Public Offering
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Closing of Initial Public OfferingNov 14, 2024 12:00:00 AM
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of Biomanufacturing
press releaseinvestorvideoARCHIVE
ARCHIVE: Invizyne’s Nasdaq IPO Marks New Era of BiomanufacturingNov 13, 2024 12:15:00 AM
ARCHIVE: Invizyne Technologies Begins Trading on NASDAQ
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Begins Trading on NASDAQNov 13, 2024 12:00:00 AM
ARCHIVE: Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies to Begin Trading on NASDAQ on November 13, 2024Nov 12, 2024 12:00:00 AM
ARCHIVE: Invizyne Technologies Announces Pricing of $15 Million Initial Public Offering
press releaseinvestorARCHIVE
ARCHIVE: Invizyne Technologies Announces Pricing of $15 Million Initial Public OfferingNov 11, 2024 12:00:00 AM
Previous page
Page 1 of 3
Next page

eXoZymes Inc.

750 Royal Oaks Dr, st 106, 
Monrovia 91016, CA, USA

P: (626) 415-1488
E: info@exozymes.com

 

© eXoZymes Inc. [Nasdaq:EXOZ] unshackling enzymes since 2019 (formerly known as Invizyne Technologies)

logo mark